32 AndroGel Lawsuit Claims Selected As Potential Low Testosterone Bellwether Trial Cases

Print

Wright & Schulte LLC Is Representing Plaintiffs In AndroGel Lawsuit Claims and Testosterone Drug Therapy Lawsuits That Allege Men Experience Heart Attack, Strokes, Blood Clots And Cardiac Death After Using Prescription Low T Drugs.

Testosterone Treatment Lawsuits-Wright-and-Schulte-LLCAttorneys representing plaintiffs and defendants in the federal multidistrict litigation (MDL) for AndroGel lawsuit claims have submitted a list of 32 AndroGel lawsuits as potential cases for bellwether trials. Lawsuits regarding AndroGel testosterone products will be the first to go to a jury although other complaints in the MDL allege that testosterone products such Androderm and Axiron, have caused men to suffer heart attacks, strokes, blood clots and cardiac death.

AndroGel lawsuit claims are being tried first since the majority of the 3,200 complaints pending in the testosterone MDL name as defendants, AbbVie and Abbot Laboratories, which makes and markets the blockbuster drug, AndroGel. On November, 2, both parties submitted their lists of 16 potential cases to U.S. District Judge Matthew F. Kennelly, who is overseeing the testosterone MDL in the U.S. District Court, Northern District of Illinois. The eight cases involving blood clotting claims and eight cardiovascular injury claims were selected from a pool of 100 AndroGel-only cases. AbbVie said in its document the defendants prefer that Judge Kennelly randomly select the 32 cases to prevent “strategic gamesmanship,” where attorneys choose cases they are most likely to win rather than select cases that are representative of all the lawsuits. Judge Kennelly will select the first six cases for bellwether trial by March 1, 2016. The first AndroGel trial is scheduled to begin in October 2016. (In re: Testosterone Replacement Therapy Product Liability Litigation – MDL No. 254)

“The first AndroGel cases that will go before juries will help determine how non-AndroGel testosterone lawsuit claims will fare in future trials,” explains Wright & Schulte LLC, a law firm representing men in testosterone complaints in this federal MDL.

The industrywide MDL for testosterone products was created in June 2014, six months after the U.S. Food and Drug Administration (FDA) launched an investigation into the safety and effectiveness of all FDA-approved prescription testosterone products. The regulatory agency reviewed studies that found cardiovascular risks associated with testosterone products. One study, published in the November 2013 issue of JAMA, indicated that low testosterone treatment products raised the risk of death, heart attack and stroke in men by about 30 percent. After reviewing more studies and seeking input from its medical advisory panels, the FDA in March, directed testosterone makers to place labels on their products warning of the potential increased risk of heart attack or stroke when taking testosterone medication.
[fda.gov/Safety/MedWatch/SafetyInformation, FDA, January, 31, 2014]
[fda.gov/Drugs/DrugSafety/ucm436259.htm, FDA, March 3, 2015]

Court documents indicate that testosterone lawsuit claims allege that men who use testosterone products such as Fortesta and Delatestryl, have experienced heart attacks, stroke, blood clots, and cardiac death. In a recently filed lawsuit against AbbVie Inc. and Abbott Laboratories, a Rhode Island man alleges that he suffered a heart attack after using AndroGel. The complaint purports the defendants advertised their drug as safe to use to treat low testosterone problems but failed to disclose the risks associated with their product. (Case No. 1:14-cv-00772, U.S. District Court, Eastern District of Illinois)

Court records show that in addition to AbbVie and Abbott Laboratories, other testosterone makers named as defendants in the MDL include:

  • Actavis, Inc. and Watson Pharmaceuticals, which makes AndroDerm
  • Auxilium Pharmaceuticals, Inc., which makes Testim
  • Endo Pharmaceuticals Inc., which makes Delatestryl and Fortesta
  • Eli Lilly and Company and Lilly USA LLC, makers of Axiron
  • Pfizer Inc. and its subsidiary, Pharmacia & Upjohn Co. which makes and markets Depo-Testosterone

(In re: Testosterone Replacement Therapy ProductLiabilityLitigation – MDL No. 2545)

About Wright & Schulte LLC: Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright Schulte LLC stand up for the rights of people who have been injured or wronged, and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free testosterone lawsuit case evaluations are available through yourlegalhelp.com, or call 1-888-399-0795.

Contact:
Wright & Schulte LLC
865 S. Dixie Dr.
Vandalia, Ohio 45377
1-800-399-0795
http://www.yourlegalhelp.com

This entry was posted in Wright & Schulte Lawsuit News. Bookmark the permalink.